
| Ethics | | Project Site R&D | Date of First Patient | |
|--------------------------|--|--------------------------|--------------------------|--|
| Committee Ref | Project Title | Submission | Consented | Benchmark Met or Reason for Delay |
| | Pharmacokinetic variation and toxicity in Ewing's sarcoma (PK | | | Delays due to external factors outside the |
| 13/NE/0225 | 2013 01) | 20/06/2014 | | control of the Sponsor and Trust |
| 14/YH/0048 | Apposition V | 23/06/2014 | 09/07/2014 | Benchmark met |
| 13/EE/0397 | NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer) WA29231- LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN | 01/07/2014 | 18/12/2014 | Delays due to external factors outside the control of the Sponsor and Trust |
| | PATIENTS WITH POLYARTICULAR-COURSE AND SYSTEMIC | | 4.5 /07 /004.4 | |
| 14/NE/0122 | JUVENILE IDIOPATHIC ARTHRITIS | 11/06/2014 | 16/07/2014 | Benchmark met Delays due to external factors outside the |
| 13/LO/0716 | CCRN 2159 (Uveitis) | 25/06/2014 | | control of the Sponsor and Trust |
| 13/LO/0717 | CL3-78989-006. EYEGUARD-C study | 25/06/2014 | 28/01/2015 | Delays due to external factors outside the control of the Sponsor and Trust |
| 13/LO/1608 | Study of efficacy and safety of nilotinib in paediatric CML patients | 07/07/2014 | 16/12/2014 | Delays due to external factors outside the control of the Sponsor and Trust Delays due to external factors outside the |
| 14/EM/0034 | NCRN3025 - GDC-0199 in CLL (GO28667) - MURANO | 16/07/2014 | 22/10/2014 | control of the Sponsor and Trust |
| 13/LO/1329 | 3H (Hemodiafiltration, Heart and Heights) study | 28/07/2014 | | Benchmark met |
| | InterAACT - A Multicentre Randomised Phase II Advanced Anal | | | Delays due to external factors outside the |
| 13/LO/1463 | Cancer Trial | 14/08/2014 | | control of the Sponsor and Trust |
| 14/EE/0105 | EORTC protocol 26101 | 19/08/2014 | 15/09/2014 | Benchmark met |
| 13/NW/0702 | ABC-06: ASC alone or with mFOLFOX for advanced biliary tract cancer | 20/08/2014 | 10/12/2014 | Delays due to external factors outside the control of the Sponsor and Trust |
| 14/NW/0008 | GO-COLITIS | 26/08/2014 | 23/12/2014 | Reasons for delay rest with the Sponsor |
| 13/LO/1515 | Predicting Language Outcome & Recovery after Stroke | 26/08/2014 | | Benchmark met |
| 14/LO/0203 | CLARITY | 28/08/2014 | 01/10/2014 | Benchmark met |
| 12/514/0205 | Treatment of Advanced Clausers Study (TACS) | 04/00/2014 | 12/02/2015 | Delays due to external factors outside the |
| 13/EM/0395 | Treatment of Advanced Glaucoma Study (TAGS) The effect of Plasma Rich in Growth Factors (PRGF) on periodontal | | | control of the Sponsor and Trust |
| 14/SW/0114 | tissue regeneration NCRN - 2890: Quizartinib (AC220) Monotherapy vs. Salvage | 28/08/2014 | 01/10/2014 | Benchmark met Delays due to external factors outside the |
| 14/EM/0130 | Chemotherapy | 15/09/2014 | 08/01/2015 | control of the Sponsor and Trust |
| | | | | Delays due to external factors outside the |
| 13/EE/0367 | CCRN 2215 (Crohn's) | 05/09/2014 | | control of the Sponsor and Trust |
| 13/EM/0149 | 15961 GadaCAD1 | 18/09/2014 29/09/2014 | | Reasons for delay rest with the Trust Benchmark met |
| 14/WM/0159 12/NW/0790 | The SNIFFLE 2 Study The BASICS Trial | 03/10/2014 | | Benchmark met |
| 14/NW/1256 | RVENCH | 29/09/2014 | | Benchmark met |
| 11/H1307/6 | SWITCH | 14/10/2014 | | Benchmark met |
| 13/SC/0619 | Group B streptococcus Immunisation Attitudes | 01/10/2014 | 23/10/2014 | Benchmark met |
| 13/EM/0154 | SWIFFT Trial | 04/09/2014 | | Benchmark met |
| 14/NS/0089 | Нір 'Ор | 17/10/2014 | | Delays due to external factors outside the control of the Sponsor and Trust |
| 14/SC/0221 | CONCEPT: A Phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of Her2 negative metastatic breast cancer (mBC) | 21/10/2014 | 18/12/2014 | Benchmark met |
| | AZD9291 v chemotherapy in NSCLC, following EGFR TKI therapy | | | Delays due to external factors outside the |
| 14/EE/1063 | (AURA3) | 29/10/2014 | 13/01/2015 | control of the Sponsor and Trust |
| 12/50/0007 | An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients with Relapsed or Refractory Solid Tumors Followed by a | 02/11/2014 | 28/11/2014 | Bonshmark met |
| 13/SC/0007 12/WM/0187 | Dose Expansion Phase in Patients With Unresectable Melanoma. ROCSS | 03/11/2014 | | Benchmark met Benchmark met |
| L2/WW/0187 | OTO-104 in Meniere's Disease | 13/11/2014 | | Benchmark met |
| , , | The effect of Plasma Rich in Growth Factors (PRGF) on the | -,, -014 | ,, _014 | |
| 14/SW/1101 | treatment of dry sockets | 03/11/2014 | 24/11/2014 | Benchmark met |
| 14/WM/0085 | Robot Assisted Fracture Surgery (RAFS) | 12/11/2014 | 19/12/2014 | Benchmark met |
| 14/SC/1014 | CANC - 3482 JANUS 1: Ruxolitinib or placebo + Capecitabine in pancreatic adenocarcinoma | 20/11/2014 | 21/01/2015 | Benchmark met |
| | | . , | | Delays due to external factors outside the |
| 14/LO/1428 | Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study | 01/12/2014 | | control of the Sponsor and Trust |
| 14/SC/1269 | CAIRO WPC: PROXY: Post ROSC OXYgenation Study | 18/12/2014 | | Benchmark met |
| 07/H0718/57 | UKAITPR | 18/12/2014 | 08/01/2015 | Benchmark met |
| 12/50/0200 | CCDN2100 (Custic fibracia) | 00/12/2011 | 17/04/2015 | Descent for delay rest with the Course |
| 13/SC/0268 | CCRN2100 (Cystic fibrosis) | 09/12/2014 | | Reasons for delay rest with the Sponsor |
| 14/SW/1078 | DRIFT School age follow-up | 14/01/2015 | 07/02/2015 | Benchmark met Delays due to external factors outside the |
| 13/WM/0143 14/LO/1043 | Study of Moxetumomab Pasudotox in pALL or LL of B-Cell LEAVO | 22/01/2015 23/01/2015 | 16/02/2015 | control of the Sponsor and Trust Benchmark met |
| 14/YH/0085 | FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab | 16/01/2015 | | Benchmark met |
| | The benefit of ultrasound imaging prior to heart bypass surgery to | | | |
| 14/EM/1319 | prevent leg wound complications. | 30/01/2015 | 0010-1 | Benchmark met |

Performance First Patient Visit Benchmark

| | | Project Site | Date of First | |
|--------------------------|--|--------------------------|---------------|--|
| Ethics | | R&D | Patient | |
| Committee Ref | Project Title | Submission | Consented | Benchmark Met or Reason for Delay |
| 13/WA/0205 | AML18 | 10/02/2015 | 06/03/2015 | Benchmark met |
| 14/SC/1425 | CCRN 2738 (AMD) | 12/02/2015 | 25/02/2015 | Benchmark met |
| | | | | Delays due to external factors outside the |
| 14/LO/1617 | GLP110933 study Type I DM Study (DRN 3266) | 06/02/2015 | 27/05/2015 | control of the Sponsor and Trust |
| | | | | Delays due to external factors outside the |
| 14/NI/1075 | CHIL3670 (ALX0171-C104) | 16/02/2015 | | control of the Sponsor and Trust |
| | GA29103: PHASE III, RANDOMIZED, MULTICENTER DOUBLE- | | | |
| | BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND | | | |
| | SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN | | | |
| | PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE | | | |
| 14/NE/1099 | COLITIS WHO ARE NAIVE TO THE INHIBITORS | 27/02/2015 | | Reasons for delay rest with the Trust |
| 14/10/1000 | | 27,02,2013 | | Delays due to external factors outside the |
| 14/EM/0215 | M12-914 Phase III Veliparib/Placebo + C/P Breast Cancer Study | 02/03/2015 | | control of the Sponsor and Trust |
| 14/YH/1124 | EXTEND (2819MA1002) | 04/03/2015 | | Reasons for delay rest with the Trust |
| 14/11/1124 | CHIL3846 Abbott Sensor Based Glucose Monitoring System | 04/03/2013 | | neusons for delay rest with the trust |
| 14/WM/1228 | Paediatric Study (BEAGLE) | 05/03/2015 | 01/04/2015 | Benchmark met |
| | | | | Delays due to external factors outside the |
| 15/NW/0009 | MCRN3127 (20130173) | 17/03/2015 | 24/06/2015 | control of the Sponsor and Trust |
| 14/NW/1067 | PROteKT | 24/03/2015 | 26/06/2015 | Reasons for delay rest with the Sponsor |
| 14/1007 | | 24/03/2013 | 20/00/2013 | Delays due to external factors outside the |
| 13/LO/0451 | The UK TAVI Trial | 07/04/2015 | | control of the Sponsor and Trust |
| 12/SC/0090 | Dual Erb B Inhibition in Oesophago-gastric Cancer | 08/04/2015 | | Benchmark met |
| 14/SC/0181 | Elagolix in Endometriosis Associated Pain - Extension | 10/04/2015 | | Benchmark met |
| 11/SC/0173 | VIABLE | 28/04/2015 | | Benchmark met |
| 12/EE/0368 | Adrenal study | 12/05/2015 | | Benchmark met |
| 12/22/0500 | | ,, | | |
| 15/LO/0104 | Albumin To prevenT Infection in chronic liveR failurE (ATTIRE) | 13/05/2015 | 03/06/2015 | Benchmark met |
| GTAC 128 | WT1 TCR-001 | 15/05/2015 | | 70 days not yet reached |
| 14/SC/1311 | MCRN3165 (SD744) Cubist PSI Osteomyelitis | 20/05/2015 | | 70 days not yet reached |
| 14/500/1016 | | 22/04/2045 | 15/06/2015 | Den skunsul, met |
| 14/SW/1016 | Validity of the Children's Cognitive Screening Instrument (CCOSI) An Exploratory RCT of a Psychosocial Group Intervention for | 23/04/2015 | 15/06/2015 | Benchmark met |
| 14/WS/1149 | | 12/06/2015 | | 70 days not yet reached |
| | Epilepsy NCRN - 3245 - Betalutin radioimmunotherapy for treatment of | 12/06/2015 | | 70 days not yet reached |
| 14/NU/1027 | | 16/06/2015 | | 70 days not yet reached |
| 14/NI/1037 14/YH/1263 | relapsed CD37+ NHL GLYSURE Study | 16/06/2015 19/05/2015 | | 70 days not yet reached 70 days not yet reached |
| | | | | |
| 15/SC/0054 | CheckMate 238 (Nivolumab vs Ipilimumab in Melanoma) | 22/06/2015 | | 70 days not yet reached |



3